Latest Articles

Publication Date
Tolerability and Shared Decision-Making in the Hormonal Management of Endometriosis-Associated Pain.

Background: The management of endometriosis-associated pain has traditionally focused on analgesic efficacy. However, with high-level evidence demonstrating therapeutic equivalence among principal hormonal classes, the paradigm has shifted towards a patient-centred …

Published: Sept. 18, 2025, midnight
Efficacy of Elagolix and Relugolix for the Treatment of Pelvic Pain in Patients With Endometriosis: A Systematic Review.

Endometriosis is a chronic gynecological condition commonly associated with pelvic pain, dysmenorrhea, dyspareunia, and infertility. Owing to the limitations and adverse effects of traditional hormonal therapies, this study aimed to …

Published: Sept. 12, 2025, midnight
Safety of current strategies to manage moderate to severe pain in patients with endometriosis.

Medical therapy is crucial in the long-term management of endometriosis, and its clinical efficacy must be balanced with a favorable safety profile.

Published: Aug. 25, 2025, midnight
Comparison of quality of life in patients with endometriosis undergoing treatment with progestins, oral contraceptives pills (OCP), and GnRH agonists.

The objective of this study was to compare the quality of life in patients with endometriosis undergoing treatment with progestins, OCPs, and GnRH agonists.

Published: Aug. 20, 2025, midnight
Fertility preservation in women with endometriosis: A retrospective non-Inferiority study comparing Dienogest in the PPOS protocol to antagonist and agonist protocols.

Endometriosis is a common pathology that can lead to a decrease in fertility and is therefore a medical indication for preserving fertility. Traditionally, gonadotropin-releasing hormone (GnRH) antagonist and agonist protocols …

Published: April 3, 2025, midnight
In utero exposure to synthetic sex hormones and their multigenerational impact on neurodevelopmental disorders: Endocrine disruptors as neuroendocrine disruptors.

Synthetic sex hormones, estrogens and/or progestogens, have been widely administered without sufficient long-term studies for decades to millions of pregnant women around the world and although most were banned in …

Published: April 1, 2025, midnight
Long-term follow-up of the effect of oral dienogest and dienogest/ethinylestradiol treatment on cell-free DNA levels in patients with deep endometriosis.

Endometriosis is currently considered a systemic inflammatory disease and different non-invasive inflammatory markers, such as cell-free DNA (cfDNA), have recently been evaluated. Hormonal treatments are frequently prescribed as first-line treatments …

Published: March 21, 2025, midnight
The efficacy of progestins in managing pain associated with endometriosis, fibroids and pre-menstrual syndrome: a systematic review.

Alongside being contraceptives, progestins have been investigated as potential anti-inflammatory and analgesic therapies for use in painful gynaecological conditions. This review aims to synthesise evidence pertaining to the efficacy of …

Published: March 11, 2025, midnight
Azurocidin is Associated with Dienogest-resistance in Ovarian Endometriotic Cysts.

Endometriosis and ovarian endometrioma (OMA) cause dysmenorrhea and infertility. Current hormonal therapies for OMA treatment, may exhibit limited effectiveness. Hormonal treatments function by downregulate estrogen receptors (ERs) via progesterone receptor …

Published: Feb. 5, 2025, midnight
ESTROGEN-PROGESTINS AND ENDOMETRIOSIS-ASSOCIATED DEPRESSION:OF CAUSATION, BIAS, AND CONFOUNDING.

Published: Jan. 31, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!